Dashnaiv Peptides
Compounds·repair & anti inflammatory·unclear; NO-system and growth-factor pathways proposed

BPC-157: dosing in studies, side effects, the Wolverine stack and what the research shows

What 228 indexed publications and 0 randomized trials actually state about bpc-157, sentence by sentence, each tied to its source and labeled by the kind of evidence it is.

Observational, human Reviewed 36 sources Updated Also: Bepecin

At a glance

Evidence availability
Human clinical evidence
Strongest tier in the indexed literature
Indexed publications
228
Europe PMC, title or abstract, 2026-09-09
Human studies in ledger
2
0 randomized; study count, not efficacy proof
Approval
not approved
ChEMBL phase 1
Routes reported
intragastric, intraperitoneal, intravenous, oral, subcutaneous, topical
from studies in this ledger
Studied in
Humans, Mice, Rats
24 primary studies in the evidence table
Reviewed by Adam Mirando, PharmD, on . What changed

What BPC-157 is and how it acts

BPC-157 is a peptide in the repair & anti inflammatory class (unclear; NO-system and growth-factor pathways proposed). Europe PMC indexes 228 publications naming it or a listed alias in a title or abstract, including 0 randomized controlled trials and 0 clinical trials of any design, as of . The strongest evidence tier in that literature is observational human studies, with no indexed randomized trial.

This page reports what those studies state, sentence by sentence, with each statement tied to its source and labeled by the kind of evidence it is. It does not recommend use, and it does not translate study doses into anything personal.

What the evidence level means

Publication counts show what is indexed, not how strong the evidence is. The ledger below separates human clinical records from preclinical, analytical, and in-vitro work.

Human clinical studies in this ledger20 randomized · 2 other human clinical
Evidence strengthNot yet assessedSeparate from evidence availability
Efficacy signalNot yet assessedRead the study result, not the tier alone

Interpretation boundary: An indexed publication count is a discovery measure. It does not establish efficacy, safety, approval, or a personal treatment plan.

BPC-157 in two minutes

What it is. A 15-amino-acid fragment of a protein found in human gastric juice, synthesised in a laboratory. Studied since the early 1990s, almost entirely in rats and almost entirely by one group in Zagreb, for healing of tendon, muscle, bone, gut and nerve injury.

What the research actually shows. 228 indexed publications and zero randomized trials. Three human studies exist, all small uncontrolled pilots from one clinic in Orlando: a 2021 retrospective series of knee injections, a 2024 series of 12 women with bladder pain, and a 2025 safety infusion in two healthy adults. Together they involve about 26 people and none had a placebo group. The animal literature is large and consistent in reporting faster healing; how far that transfers to people is unknown.

What people commonly report using. 200 to 500 micrograms injected once or twice daily near an injury for four to six weeks, or oral capsules for gut complaints; the "Wolverine stack" adds TB-500. None of it has been tested.

Status. Not approved anywhere. Prohibited in sport at all times under WADA category S0. Placed by the FDA in Category 2 of its compounding bulk-substances list in 2023 for safety concerns.

Where the evidence is thinnest. Any controlled human outcome; long-term safety; whether its blood-vessel-promoting activity matters in the presence of a tumour; whether oral dosing reaches the tissues injections reach.

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

How BPC-157 is thought to work

Written from general pharmacology and the development record, and marked as editorial synthesis; the measurements behind it are quoted in the biomarker section.

  • BPC-157 is a 15-amino-acid fragment (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) of a larger protein isolated from human gastric juice, called body protection compound. The 'stable gastric pentadecapeptide' name in the literature refers to its stability in gastric acid, which is why oral and intragastric administration appear in animal studies alongside injection.Editorial synthesis
    Editorial synthesis from general knowledge
  • The proposed mechanisms come almost entirely from one research group in Zagreb over three decades: modulation of the nitric oxide system (it counteracts both raised and lowered blood pressure in rat models), upregulation of growth-factor receptors and the early growth response gene EGR-1, promotion of new blood-vessel formation through VEGFR2, activation of the FAK–paxillin pathway in tendon fibroblasts, and interactions with dopamine and serotonin systems. These are mechanisms observed in rats and in cells. None has been confirmed in a controlled human study, and the concentration of the evidence in a single laboratory is itself a limitation that reviews of the compound now note.Editorial synthesis
    Editorial synthesis from general knowledge
  • The same angiogenic and growth-factor activity that underlies the healing claims is the basis of the most-searched safety question about BPC-157: whether promoting vessel growth could feed a tumour. No study has tested this in either direction. It is a theoretical concern that follows from the mechanism, not an observed harm, and not a demonstrated safety either.Editorial synthesis
    Editorial synthesis from general knowledge

What happened in the human studies?

This record's ledger holds 2 primary human studies. Few enough to show in full: each card quotes what its abstract reported about BPC-157. Read them before any other section on this page.

  • Human study humans n = 2 2025 Observational, human
    For years, the peptide Body Protection Compound 157 (BPC-157) has been used to treat partial muscle or tendon tears.
    Source pmid-40131143 · quoted verbatim from the abstract
  • Human study humans 2021 Observational, human
    Here, an integrated approach in experimental BPC 157 therapy was implemented, combining laboratory-controlled and field study results.
    Source pmid-34571768 · quoted verbatim from the abstract

What did the studies find?

Reported outcomes, not benefits. Of 228 indexed publications, none is a randomized trial; the three human studies are small, uncontrolled pilots from one clinic. What follows is what was measured, mostly in rats. One row per primary study in this record's ledger. Fields are read from each paper's indexing and abstract. "Analytical method" marks papers about detecting or measuring the compound rather than about its effects.

24 primary studies in this record's ledger, strongest evidence first. A dash means the abstract did not state the value.
StudyDesignnSpeciesDoseRouteDurationReported outcomeTier
Lee 2025 Human study 2 Humans20 mgintravenous58 year; 68 year — Observational, human
Tlak 2021 Human study — Humans—oral— — Observational, human
Biçer 2026 Animal study — Rats10 µg/kg/day—— Biomechanical testing revealed higher maximum load to failure values in the BPC-157 and TB-500 groups compared to controls, reaching statistical significance in the TB-500 group (p Conclusion In this exploratory rat… Animal, preclinical
Jelińska 2026 Animal study — ———— Despite significantly lower potency compared to clinically used AChE inhibitors, the studied peptides represent a promising scaffold for further optimization. Animal, preclinical
Yıldırım 2026 Animal study 6 Rats20 µg/kgintraperitoneal— Bcl-2 mRNA was not significantly reduced by I/R compared with SHAM; however, BPC 157 significantly increased Bcl-2 expression compared with IR. Animal, preclinical
Smoday 2026 Animal study — Rats10 ng/kg—— — Animal, preclinical
Madzarac 2026 Animal study — Rats10 µg; 10 ngintraperitoneal— BPC 157 counteracted increase in NO level and counteracted increase in MDA level. Animal, preclinical
Sikiric 2025 Animal study — Rats, Mice——— BPC 157 exhibits a distinctive effect on NO-level (increase vs. decrease), always combined with counteraction of free radicals formation, and in mice and rats, BPC 157 therapy counteracts Parkinson's disease-like and… Animal, preclinical
Demirtaş 2025 Animal study — Rats——— The findings of this study demonstrate that BPC-157 exerts a significant protective effect against distant organ damage in the liver, kidneys, and lungs following lower extremity ischemia-reperfusion injury in rats. Animal, preclinical
Matek 2025 Animal study — Rats10 µg; 10 ngoral3 months All parameters of the walking pattern fully improved, and soon after detachment and therapy application, muscle approached the bone, leaving a minimal gap (on ultrasonic assessment), and leg contracture was annihilated. Animal, preclinical
Tepes 2023 Animal study — Rats10 µg/kg; 10 ng/kgsubcutaneous— Contrarily, BPC 157 therapy (10 µg/kg, 10 ng/kg sc) given at 3 min reperfusion times eliminated/attenuated venous hypertension (intracranial (superior sagittal sinus), portal, and caval) and aortal hypotension and… Animal, preclinical
Smoday 2023 Animal study — Rats10 µg/kg; 10 ng/kgintragastric, intraperitoneal— — Animal, preclinical
Premuzic 2023 Animal study — Rats10 µg; 10 ng/kgintragastric— — Animal, preclinical
Kalogjera 2023 Animal study — Rats10 µg—— Thrombosis, peripherally (inferior caval vein, portal vein, abdominal aorta) and centrally (superior sagittal sinus) BPC 157 therapy markedly reduced/annihilated. Animal, preclinical
Strbe 2023 Animal study — Rats10 µg/kg; 10 ng/kgintraperitoneal— — Animal, preclinical
Gamulin 2022 Animal study — Rats10 ng/kgintraperitoneal— Recently, it was found that when confronted with major vessel occlusion and vascular failure, stable gastric pentadecapeptide BPC 157 therapy might rapidly functionally improve minor vessels to take over the function… Animal, preclinical
Zemba 2022 Animal study — Rats—intraperitoneal— With the BPC 157 therapy applied immediately after ketamine, the effect on Nos1 , Nos2 , Plcg1 , Prkcg , and Ptgs2 (increased or decreased expression), appeared as a timely specific BPC 157 effect on ketamine-specific… Animal, preclinical
Smoday 2022 Animal study — Rats10 μg/kg; 10 ng/kg—— We revealed the therapy effect of the stable gastric pentadecapeptide BPC 157 (10 μg/kg, 10 ng/kg ig or po) with specific activation of the collateral rescuing pathways, the azygos vein, on bile duct ligation in… Animal, preclinical
Perovic 2022 Animal study 157 Rats—intragastric, intraperitoneal1 year; 4 days BPC 157 rats presented only discrete edema and minimal hemorrhage and increased Nos1 , Nos2 , and Nos3 values (30 min post-injury, (i)) or only mild hemorrhage, and only discrete vacuolation of tissue (day 4, (ii)). Animal, preclinical
Kralj 2021 Animal study — Rats0.4 µg; 0.4 ngintragastric, intraperitoneal, oral— As leading symptoms, increased intraocular pressure and mydriasis, as well as degeneration of retinal ganglion cells, optic nerve head excavation and reduction in optic nerve thickness, generalized severe irregularity… Animal, preclinical
Japjec 2021 Animal study — Rats10 µg/kg; 10 ng/kgintraperitoneal, oral28 days; 42 days — Animal, preclinical
Udovicic 2021 Animal study — Rats10 μg/kgintraperitoneal, subcutaneous— Monocrotaline-induced pulmonary arterial hypertension in rats (wall thickness, total vessel area, heart frequency, QRS axis deviation, QT interval prolongation, increase in right ventricle systolic pressure and… Animal, preclinical
Gojkovic 2021 Animal study — Rats10 µg/kg; 10 ng/kgintragastric, intraperitoneal, topical— BPC 157 therapy rapidly attenuates the brain swelling, rapidly eliminates the increased pressure in the ligated superior sagittal sinus and the severe portal and caval hypertension and aortal hypotension, and rapidly… Animal, preclinical
Vukojević 2018 Animal study — —10 μg; 10 ng/kg—— BPC 157-rats presented raised plasma NO-values, but normal MDA-values; in ICV tissue reverted low NO-values and counteracted increased MDA-levels. Animal, preclinical

What doses did studies use?

These are doses studies administered, almost all in rats, plus a two-person intravenous safety pilot. No trial has established a BPC-157 dose for any use in people; the 200 to 500 microgram figures that circulate come from communities and clinics. Each entry is a sentence quoted from the study's abstract, with the study's design, sample size and year in front of it. Comparator doses in the same sentence are not attributed to bpc-157.

  • Human study humans n = 2 2025 Observational, human
    Doses stated in the abstract: 20 mg
    Intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated.
    Source pmid-40131143 · quoted verbatim from the abstract, emphasis added
  • Animal study rats 2026 Animal, preclinical
    Doses stated in the abstract: 10 µg/kg/day
    Thirty-two male Sprague-Dawley rats, each aged 12 weeks and weighing approximately 330 g, underwent standardized Achilles tendon transection and repair and were randomly assigned to four groups, with eight rats in each group: control, BPC-157 (10 µg/kg/day), TB-500 (60 µg/kg/day), and combined BPC-157 + TB-500 (BPC + TB).
    Source pmid-42542926 · quoted verbatim from the abstract, emphasis added
  • Animal study rats n = 6 2026 Animal, preclinical
    Doses stated in the abstract: 20 µg/kg
    BPC 157 (20 µg/kg, intraperitoneal) was administered at the 45th minute of ischemia in B and IRB groups.
    Source pmid-42204242 · quoted verbatim from the abstract, emphasis added
  • Animal study rats 2026 Animal, preclinical
    Doses stated in the abstract: 10 ng/kg
    BPC 157 (10 ng/kg intragatrically immediately after unilateral adrenalectomy) produced a clear, reproducible separation of aortic spectra from control samples at all time points.
    Source pmid-41599787 · quoted verbatim from the abstract, emphasis added
  • Animal study rats 2026 Animal, preclinical
    Doses stated in the abstract: 10 µg; 10 ng
    Tracheocutaneous fistula rats received daily medication (/kg), alone or combined, BPC 157 therapy (10 µg, 10 ng, in drinking water or intraperitoneally) along with a triple NO-agent approach (L-NAME 5 mg, L-arginine 100 mg, and L-NAME+L-arginine, intraperitoneally).
    Source pmid-41599743 · quoted verbatim from the abstract, emphasis added
  • Animal study rats 2025 Animal, preclinical
    Doses stated in the abstract: 10 µg; 10 ng
    Pharmacotherapy recovering various muscle, tendon, ligament, and bone lesions, and severed junctions (i.e., myotendinous junction), per-oral in particular (BPC 157/kg/day 10 µg, 10 ng), provides muscle-to-bone reattachment after quadriceps muscle detachment, both complete (rectus muscle) and partial (vastus muscles).
    Source pmid-39861766 · quoted verbatim from the abstract, emphasis added

BPC-157 dosage chart: studies versus what circulates

Two kinds of figure appear when people search for a BPC-157 dose. This table keeps them apart.

Only the first two rows were administered to people, and neither was chosen to treat anything. Body-weight doses from rats do not convert to people by arithmetic.

Source of the figureDoseFrequency and durationWhat it was for
Human intravenous safety pilot (2025)10 mg and 20 mg, single infusionOnce, 24-hour observation2 healthy adults; tolerated; plasma back to baseline within 24 h
Human knee series (2021) and bladder series (2024)Local injection; doses as stated in the papersSingle or few injectionsUncontrolled series from one clinic, about 24 people in total; not in this ledger yet
Rat studies (the bulk of the literature)10 µg/kg and 10 ng/kg, the group's standard pairSingle doses to several weeksIntraperitoneal, intragastric or in drinking water; healing, gut, blood-pressure and behavioural models
Commonly reported (communities, clinics)200 to 500 µg subcutaneously, often near the injuryOnce or twice daily, 4 to 6 weeksUntested for these uses
Commonly reported, oral250 to 500 µg capsulesOnce or twice dailyRests on the gastric-stability finding in animals; no human absorption data
Commonly reported, 'Wolverine stack'BPC-157 as above plus TB-500 2 to 2.5 mgTB-500 twice weeklyOne 2026 rat study tested the pair on tendon healing; nothing in people

The rat doses are notable for how small they are: 10 nanograms per kilogram is a thousand times below the common human figure per kilogram of body weight. That gap is one reason the community figures cannot be called derived from the studies; they were not.

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

What side effects have been reported?

Events and their frequency as each study reported them, with the denominator where the abstract gives one.

  • Human study humans n = 2 2025 Observational, human
    The BPC-157 peptide infusion was tolerated, with no side effects reported.
    Source pmid-40131143 · quoted verbatim from the abstract
  • Animal study rats 2022 Animal, preclinical
    BPC 157 counteracted ketamine-cognition dysfunction, social withdrawal, and anhedonia, and exerted additional anxiolytic effect.
    Source pmid-35884767 · quoted verbatim from the abstract

Who BPC-157 is discussed for, and the cautions that recur

There is no approved indication and no approved patient. What follows is the reasoning that appears in reviews and regulatory statements.

The interest. Tendon, ligament and muscle injuries, post-surgical recovery, and inflammatory gut conditions, because that is where the rat studies report effects and because injection near an injury is easy to do. Athletes, who make up much of the audience, are the group for whom it is explicitly prohibited.

Cautions that recur.

  • Cancer, active or recent. The compound promotes new blood-vessel growth and upregulates growth-factor signalling in animals. Whether that matters in a person with a tumour is untested in either direction, and every serious review lists it first.
  • Blood pressure medication and nitric-oxide-active drugs. BPC-157 alters nitric-oxide signalling and shifts blood pressure in rats in both directions; interactions with antihypertensives, nitrates or PDE-5 inhibitors have not been studied.
  • Pregnancy and breastfeeding. No data.
  • Immunogenicity and impurities. The FDA's stated reasons for the Category 2 listing: a peptide of this size can provoke an immune response, and unregulated products carry unknown impurities.
  • Anyone subject to anti-doping rules. S0, prohibited at all times, detectable.

None of these is an observed harm in a person; all follow from the mechanism or from the absence of data. Their absence from marketing pages is a gap in those pages, not evidence of safety.

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

What studies measured: blood pressure, nitric oxide, healing markers

Laboratory and clinical measures the studies report tracking, including which hormones did and did not change.

  • Human study humans n = 2 2025 Observational, human
    On day 2, fasting blood work was repeated, vital signs were recorded, and 20 mg of BPC-157 in 250 cc of normal saline was infused over one hour.
    Source pmid-40131143 · quoted verbatim from the abstract
  • Human study humans 2021 Observational, human
    Those results were complemented by strong and visible LAP activity, particularly noticeable in the apical parts of the epithelial cells in the mid-guts of young worker honeybees originated from treated hives, suggesting a link between alternative oral therapy with BPC 157 and honeybees' immunity.
    Source pmid-34571768 · quoted verbatim from the abstract
  • Animal study 2026 Animal, preclinical
    In this study, the inhibitory potential of the gastric pentadecapeptide BPC-157 and two newly designed hybrid analogs, CIARA-1 and CIARA-2, was investigated for the first time.
    Source pmid-42278509 · quoted verbatim from the abstract
  • Animal study rats n = 6 2026 Animal, preclinical
    Body Protection Compound-157 (BPC 157), a stable gastric pentadecapeptide, has demonstrated cytoprotective properties in multiple tissues.
    Source pmid-42204242 · quoted verbatim from the abstract
  • Animal study rats 2026 Animal, preclinical
    Stable gastric pentadecapeptide BPC 157 therapy was found to maintain the vascular function under severe stress, as FTIR spectroscopy recently demonstrated rapid peptide-induced molecular changes in healthy rat blood vessels, particularly in lipid content and protein secondary structure.
    Source pmid-41599787 · quoted verbatim from the abstract
  • Animal study rats 2026 Animal, preclinical
    Stable gastric pentadecapeptide BPC 157 was proposed.
    Source pmid-41599743 · quoted verbatim from the abstract

Reported interactions

Sentences in which the compound is studied alongside another agent. Read the quotation: the word interaction can also be statistical.

  • Animal study rats 2026 Animal, preclinical
    Three independent reviewers searched the PubMed database using permutations of peptide search terms (BPC-157, TB-500, CJC-1295, MK-677 [ibutamoren], ipamorelin, and GHK-Cu) combined with musculoskeletal tissue search terms (bone, fracture, muscle, tendon, ligament, meniscus, and cartilage) following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.
    Source pmid-42578445 · quoted verbatim from the abstract
  • Animal study 2026 Animal, preclinical
    The hybrid peptides were rationally designed by combining a BPC-157-derived fragment with an arginine-containing C-terminal sequence to enhance interactions with the enzyme's active and peripheral binding sites.
    Source pmid-42278509 · quoted verbatim from the abstract
  • Animal study rats, mice 2025 Animal, preclinical
    BPC 157 exhibits a distinctive effect on NO-level (increase vs. decrease), always combined with counteraction of free radicals formation, and in mice and rats, BPC 157 therapy counteracts Parkinson's disease-like and Alzheimer's disease-like disturbances.
    Source pmid-41155565 · quoted verbatim from the abstract
  • In vitro study humans 2023 Mechanistic, in vitro
    Thus, a stable isotope labeling-based nontargeted strategy combined with ultra-high-performance liquid chromatography-high-resolution mass spectrometry (UHPLC-HRMS) was first proposed for the effective and rapid metabolism analysis of small-molecule doping agents and demonstrated via its application to a novel doping BPC-157.
    Source pmid-37959764 · quoted verbatim from the abstract

What happens after a dose, and what people report over weeks

Hours are partly measured; weeks are reported. They should not be read in the same voice.

Measured. After intravenous infusion in two adults, plasma levels returned to baseline within 24 hours and cardiac, liver, kidney and thyroid markers did not change. That is the whole of the human pharmacokinetic record. In rats, healing effects are reported over days to weeks depending on the tissue model.

Commonly reported, untested. Users describe reduced pain at an injury within one to two weeks, gut symptom changes over similar timescales, and a course of four to six weeks. Most soft-tissue injuries improve over exactly that period without treatment, which is what a control group would have shown and why none of these accounts can be read as effect.

What would change the picture. A placebo-controlled trial in a defined injury with an objective endpoint. None has been registered.

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

How long did studies run?

A study's duration is how long the experiment ran, in rats for the most part. It is not a course length for people, and none has been tested. Treatment and follow-up periods as stated in each abstract.

  • Human study humans n = 2 2025 Observational, human
    Durations stated: 58 year; 68 year
    Two patients participated: a 58-year-old Asian male and a 68-year-old Caucasian female, each of whom had received intravenous BPC-157 before this trial.
    Source pmid-40131143 · quoted verbatim from the abstract
  • Animal study rats 2025 Animal, preclinical
    Durations stated: 3 months
    Consequently, at 3 months, the form was stable, and the balance between the muscle and bone was the following: well-organized bone, newly formed as more cortical bone providing a narrower bone marrow space, and the muscle and mature fibers were oriented parallel to the bone axis and were in close contact with bone.
    Source pmid-39861766 · quoted verbatim from the abstract, emphasis added
  • Animal study rats n = 157 2022 Animal, preclinical
    Durations stated: 1 year; 4 days
    Besides the demonstrated rapid and sustained recovery (1 year), we showed the particular points of the immediate effect of the BPC 157 therapy that began rapidly after its administration, (i) soon after injury (10 min), or (ii) later (4 days), in the rats with a definitive spinal cord injury.
    Source pmid-35678659 · quoted verbatim from the abstract, emphasis added
  • Animal study rats 2021 Animal, preclinical
    Durations stated: 28 days; 42 days
    Microscopically, there are no more inflammatory infiltrate, well-oriented recovered tissue of musculotendon junction appears in BPC 157 treated rats at the 28 days and 42 days.
    Source pmid-34829776 · quoted verbatim from the abstract, emphasis added

Oral or injected: what routes studies used

Routes of administration named in each study.

  • Human study humans n = 2 2025 Observational, human
    administration by intravenous route reported
    Few studies on humans have been published, with none on the intravenous use of BPC-157 in humans.
    Source pmid-40131143 · quoted verbatim from the abstract
  • Human study humans 2021 Observational, human
    administration by oral route reported
    Those results were complemented by strong and visible LAP activity, particularly noticeable in the apical parts of the epithelial cells in the mid-guts of young worker honeybees originated from treated hives, suggesting a link between alternative oral therapy with BPC 157 and honeybees' immunity.
    Source pmid-34571768 · quoted verbatim from the abstract
  • Animal study rats n = 6 2026 Animal, preclinical
    administration by intraperitoneal route reported
    BPC 157 (20 µg/kg, intraperitoneal) was administered at the 45th minute of ischemia in B and IRB groups.
    Source pmid-42204242 · quoted verbatim from the abstract
  • Animal study rats 2026 Animal, preclinical
    administration by intraperitoneal route reported
    Tracheocutaneous fistula rats received daily medication (/kg), alone or combined, BPC 157 therapy (10 µg, 10 ng, in drinking water or intraperitoneally) along with a triple NO-agent approach (L-NAME 5 mg, L-arginine 100 mg, and L-NAME+L-arginine, intraperitoneally).
    Source pmid-41599743 · quoted verbatim from the abstract
  • Animal study rats 2025 Animal, preclinical
    administration by oral route reported
    This is a novel rat study using native peptide therapy, focused on reversing quadriceps muscle-to-bone detachment to reattachment and stable gastric pentadecapeptide BPC 157 per-oral therapy for shared muscle healing and function restoration.
    Source pmid-39861766 · quoted verbatim from the abstract
  • Animal study rats 2023 Animal, preclinical
    administration by subcutaneous route reported
    Contrarily, BPC 157 therapy (10 µg/kg, 10 ng/kg sc) given at 3 min reperfusion times eliminated/attenuated venous hypertension (intracranial (superior sagittal sinus), portal, and caval) and aortal hypotension and counteracted the increases in organ lesions and malondialdehyde values (blood ˃ heart, lungs, liver, kidney ˃ brain, gastrointestinal tract).
    Source pmid-38004420 · quoted verbatim from the abstract

Weight-normalized doses, as published

Per-kilogram figures exactly as each study published them, for the species it studied.

  • Animal study rats 2026 Animal, preclinical
    Weight-normalized doses as published: 10 µg/kg/day
    Thirty-two male Sprague-Dawley rats, each aged 12 weeks and weighing approximately 330 g, underwent standardized Achilles tendon transection and repair and were randomly assigned to four groups, with eight rats in each group: control, BPC-157 (10 µg/kg/day), TB-500 (60 µg/kg/day), and combined BPC-157 + TB-500 (BPC + TB).
    Source pmid-42542926 · quoted verbatim from the abstract, emphasis added
  • Animal study rats n = 6 2026 Animal, preclinical
    Weight-normalized doses as published: 20 µg/kg
    BPC 157 (20 µg/kg, intraperitoneal) was administered at the 45th minute of ischemia in B and IRB groups.
    Source pmid-42204242 · quoted verbatim from the abstract, emphasis added
  • Animal study rats 2026 Animal, preclinical
    Weight-normalized doses as published: 10 ng/kg
    BPC 157 (10 ng/kg intragatrically immediately after unilateral adrenalectomy) produced a clear, reproducible separation of aortic spectra from control samples at all time points.
    Source pmid-41599787 · quoted verbatim from the abstract, emphasis added
  • Animal study rats 2023 Animal, preclinical
    Weight-normalized doses as published: 10 µg/kg; 10 ng/kg
    Contrarily, BPC 157 therapy (10 µg/kg, 10 ng/kg sc) given at 3 min reperfusion times eliminated/attenuated venous hypertension (intracranial (superior sagittal sinus), portal, and caval) and aortal hypotension and counteracted the increases in organ lesions and malondialdehyde values (blood ˃ heart, lungs, liver, kidney ˃ brain, gastrointestinal tract).
    Source pmid-38004420 · quoted verbatim from the abstract, emphasis added
  • Animal study rats 2023 Animal, preclinical
    Weight-normalized doses as published: 10 µg/kg; 10 ng/kg
    At 5 min after laurate injection, stable gastric pentadecapeptide BPC 157 was implemented as therapy (10 µg/kg, 10 ng/kg intraperitoneally or intragastrically).
    Source pmid-37895979 · quoted verbatim from the abstract, emphasis added
  • Animal study rats 2023 Animal, preclinical
    Weight-normalized doses as published: 10 ng/kg
    BPC 157 therapy (10 µg, 10 ng/kg given intragastrically at 5 min or 90 min sotalol-time) effectively counteracted sotalol-occlusion/occlusion-like syndrome.
    Source pmid-37513889 · quoted verbatim from the abstract, emphasis added

Weight-normalized figures above are reproduced exactly as each study published them, for the species it studied. Dose does not scale linearly with body mass between species: metabolic rate, clearance and receptor density differ, and regulatory guidance uses allometric, not proportional, conversion. A mg/kg figure from a rat study is a fact about that rat study and nothing else.

What people report outside the literature

What circulates in user communities and clinic marketing, reported so a reader knows the figures and their origin. None of it has been tested in a trial, and none of it is a suggestion.

  • Outside the literature, BPC-157 is most often discussed at 200 to 500 micrograms by subcutaneous injection once or twice daily, commonly near the site of an injury, for four to six weeks, or as oral capsules of similar mass for gut complaints on the reasoning that the peptide survives stomach acid. The 'Wolverine stack' pairs it with TB-500, typically at 2 to 2.5 milligrams of TB-500 twice weekly. These figures circulate in forums, on Reddit and in clinic marketing; no trial has tested any of them for any outcome, and their consistency across sites reflects copying rather than evidence.Editorial synthesis
    Editorial synthesis from general knowledge
  • Effects people report are faster recovery from tendon and ligament injuries, reduced joint pain within one to two weeks, and improvement in gut symptoms; reported side effects are injection-site redness, transient dizziness, nausea, fatigue and headache. Before-and-after accounts are uncontrolled self-report over a timescale in which most soft-tissue injuries improve on their own. The two-person intravenous pilot is the only human safety measurement, and it reported no side effects over a 24-hour observation.Editorial synthesis
    Editorial synthesis from general knowledge

Reconstituting BPC-157: concentrations for common vial sizes

BPC-157 is sold as a freeze-dried powder dissolved before injection. The arithmetic is exact; the choice of what to draw is not made here.

Concentration is mass divided by volume. Adding bacteriostatic water to a vial gives the concentrations below; the last column is the volume that would contain 250 µg, purely as a worked example.

VialDiluent addedConcentrationVolume holding 250 µg on a U-100 syringe
5 mg2 mL2,500 µg/mL0.10 mL (10 units)
5 mg2.5 mL2,000 µg/mL0.125 mL (12.5 units)
10 mg2 mL5,000 µg/mL0.05 mL (5 units)
10 mg4 mL2,500 µg/mL0.10 mL (10 units)

Frequent errors: reading 5 mg as 5 mL; assuming the labelled mass is all peptide when certificates commonly show 80 to 95 percent net peptide content; using sterile rather than bacteriostatic water in a vial that will be drawn from for weeks. The reconstitution calculator shows its formula.

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

Method note · shared across compounds

Reconstitution mathematics

Lyophilised peptide is supplied as a mass in a vial and dissolved in a stated volume of diluent. Two figures follow from that and nothing else:

  • Concentration = mass in vial ÷ diluent volume. A 5 mg vial in 2 mL is 2.5 mg/mL, or 2,500 mcg/mL.
  • Volume for a given mass = that mass ÷ concentration. 250 mcg at 2,500 mcg/mL is 0.1 mL. On a U-100 insulin syringe, where 1 mL is 100 units, that is 10 units.

Study doses on this page are quoted as published, in the units the authors used. Converting between mcg, mg and IU, or between a mass and a syringe volume, is arithmetic; deciding a mass is not, and this page does not do it. The reconstitution calculator performs the conversion with the formula shown.

Method note · shared across compounds

Reading a certificate of analysis

A certificate of analysis is a laboratory report on one batch. Reading it means checking four things in order.

  1. Identity. Mass spectrometry should report an observed molecular mass matching the peptide's theoretical mass within the instrument's stated tolerance. A certificate with no mass spectrometry, or one that lists only the expected value, has not confirmed identity.
  2. Purity. HPLC purity is the area of the main peak as a share of all peaks, at a stated wavelength. It says nothing about what the other peaks are, and it is not a measure of quantity.
  3. Quantity. Net peptide content, by amino acid analysis or UV, is the fraction of the vial's mass that is peptide rather than counter-ions and water. A 5 mg vial at 80% net content holds 4 mg of peptide, and every concentration figure above changes accordingly.
  4. Provenance. The batch number on the certificate should match the vial, the laboratory should be named and independent of the seller, and the test date should be recent.

This page rates no supplier and links to none. It describes how to read the document.

Method note · shared across compounds

Equipment described in studies

Published human studies of injectable peptides report the same small set of materials: single-use insulin syringes with fixed needles, most often U-100 with 29 to 31 gauge needles; bacteriostatic water or sterile water for injection as diluent, with the choice stated in the methods; alcohol swabs; and refrigerated storage of reconstituted solution. Animal studies more often report intraperitoneal or intragastric administration and state the vehicle used. Where a study in this record's ledger names its materials or vehicle, that sentence appears under storage or routes above; where it does not, nothing is assumed here.

Storage and handling

As a powder, refrigerated at 2 to 8 °C or frozen at −20 °C, away from light and moisture; suppliers' stability statements vary, and a certificate of analysis dated near purchase matters more than a generic figure. Once dissolved in bacteriostatic water, commonly refrigerated and used within about four weeks. The "stable gastric" property in the compound's name describes survival in stomach acid, which is a statement about the molecule in vivo, not about a vial on a shelf. Cloudiness, colour or particles in a solution that was clear are reasons to discard it.

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

Blood tests and monitoring that appear in the literature

Nothing has been validated for BPC-157. This is what the one human safety study measured and what reviews suggest watching, given the mechanism.

MeasureWhy it appearsWhen it is typically drawn
Cardiac, liver, kidney and thyroid panelsMeasured in the 2025 infusion pilot; unchanged over 24 hoursBaseline, and after a course
Blood pressureThe nitric-oxide mechanism shifts it in ratsBaseline and periodically
Fasting glucoseMeasured in the pilot; unchangedBaseline
Complete blood countGeneral surveillance for an unregulated injectableBaseline
Imaging or function of the injured tissueThe only way a healing claim could be checkedBefore and after, if it is to mean anything

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

Common mistakes in how BPC-157 is discussed

  • Counting publications as evidence. 228 papers sounds substantial; zero are randomized trials and the human total is about 26 people without a control group.
  • Calling the pilots "trials". They are case series from one clinic. Their results are hypotheses, not findings.
  • Treating gastric stability as oral efficacy. Surviving acid says nothing about reaching a tendon.
  • Deriving the human dose from the rat dose. The rat figures are nanograms to micrograms per kilogram; the human figures are orders of magnitude higher and came from nowhere in particular.
  • Assuming the Wolverine stack was studied in people. One rat tendon study tested the pair in 2026. That is the entire combination evidence.
  • Calling it legal because it is sold. Not approved, restricted for compounding, prohibited in sport.
  • Assuming the vial contains what the label says. An independent certificate of analysis matched to the batch is the only check.

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

BPC-157 vs TB-500, GHK-Cu and KPV

The compounds it is most often compared with and stacked with. None is approved for these uses.

CompoundMechanism (proposed)Human evidenceStatus
BPC-157Gastric-juice protein fragment; NO system, growth-factor receptors, angiogenesisRats, extensively; 3 uncontrolled human pilotsNot approved; FDA 503A Category 2; WADA S0
TB-500 (thymosin β4 fragment)Actin-binding; cell migration and angiogenesisHuman trials of thymosin β4 in wound and eye conditions; TB-500 fragment itself less studiedNot approved; WADA S2
GHK-CuCopper-binding tripeptide; gene-expression modulation, collagen synthesisHuman trials mostly topical, in skinCosmetic use; not approved as a drug; not prohibited by name
KPVα-MSH fragment; anti-inflammatory via melanocortin signallingAnimal and cell studies; no human trialsNot approved

The head-to-head page for BPC-157 vs TB-500 holds the one animal study that tested them together. GHK-Cu, KPV and TB-500 have their own records; the repair and anti-inflammatory class page lists them all.

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

Other compounds in its class

Same class in the registry: GHK-Cu, KPV, TB-500. Each row shows what that compound's own record states; nothing is inferred across rows. Head-to-head evidence, where any exists, is on the comparison page: BPC-157 vs TB-500.

4 compounds in the repair & anti inflammatory class. Each row states what that compound's own record says; nothing is inferred across rows.
CompoundTierPublicationsRCTsRecord
BPC-157 Observational, human 228 0 draft
GHK-Cu Human clinical trial 169 1 draft
KPV Animal, preclinical 138 0 draft
TB-500 Human clinical trial 1,257 7 draft

The Wolverine stack: BPC-157 with TB-500

Whether any indexed study tested BPC-157 together with the compounds it is commonly combined with. A count of zero is the finding, not a gap in this page.

Is BPC-157 approved, banned or restricted?

Registry facts only. Jurisdiction-level status, compounding categories and sport prohibitions need their own cited documents before they appear here.

  • ChEMBL CHEMBL4297358: maximum clinical phase 1. Jurisdiction-level status pending human review.Human clinical trial
    Registry entry
  • U.S. Anti-Doping Agency Approved label
    BPC-157 is prohibited under the S0 Non-Approved Substances category of the List.
    Source usada-bpc-157-prohibited · quoted verbatim from the abstract
  • U.S. Anti-Doping Agency: not approved for human clinical use by the FDA or any other health authority, and no human clinical trials establish efficacy for any diagnosis or treatment.Approved label
    Source usada-bpc-157-prohibited
  • United States compounding: in September 2023 the FDA placed BPC-157 in Category 2 of its interim list of bulk drug substances nominated for compounding under section 503A, the category for substances with significant safety concerns, citing immunogenicity risk, peptide-related impurities and the absence of human safety data. Category 2 substances may not be used in compounding while under evaluation. Sale as a 'research chemical' is not approval and does not make personal use lawful in every jurisdiction.Editorial synthesis
    Editorial synthesis from general knowledge · primary document to be added to the ledger

Open questions and limitations

What is genuinely unknown, stated plainly. A missing field is not evidence that the outcome is safe, effective, or established.

  • No study in this record's ledger reports dose-escalation schedules for BPC-157.
  • No study in this record's ledger reports exclusion criteria for BPC-157.
  • No study in this record's ledger reports onset or duration of effects for BPC-157.
  • No randomized controlled trial of BPC-157 is indexed in Europe PMC.

Questions people ask

How long is BPC-157's half-life?

No indexed study reports a half-life for BPC-157 in people. The 2025 intravenous pilot reported plasma levels returning to baseline within 24 hours after infusion in two adults, which bounds it but does not measure it. Community claims of a four-hour half-life have no published source.

What is BPC-157?

A synthetic 15-amino-acid fragment of a protein found in human gastric juice, studied since the 1990s mostly in rats for healing of tendon, muscle, bone, gut and nerve injury. It is not an approved medicine.

What does BPC-157 do?

In rats it speeds healing in many injury models and modulates blood pressure through the nitric oxide system. In people, three small uncontrolled pilots from one clinic report tolerability and symptom improvement; no controlled trial has measured any effect.

What is the Wolverine stack?

The community name for BPC-157 combined with TB-500. One 2026 rat study tested the pair on Achilles tendon healing; no human study has. The stack page holds what exists.

What dose of BPC-157 did studies use?

Rat studies mostly used 10 micrograms or 10 nanograms per kilogram. The only human dosing data are a two-person intravenous pilot at 10 and 20 milligrams and local injections in two small case series. The 200 to 500 microgram figures that circulate did not come from any study.

What are the side effects of BPC-157?

The two-person infusion pilot reported none over 24 hours. Community reports describe injection-site redness, dizziness, nausea, fatigue and headache. Long-term safety, and the theoretical concern about promoting blood-vessel growth near a tumour, have not been studied.

Is BPC-157 FDA approved?

No. In 2023 the FDA placed it in Category 2 of its compounding bulk-substances list, the category for significant safety concerns, citing immunogenicity, impurities and the lack of human safety data.

Is BPC-157 banned in sport?

Yes. USADA states it is prohibited under WADA category S0, non-approved substances, at all times.

Can BPC-157 be taken orally?

Animal studies used intragastric dosing and drinking water, relying on the peptide's stability in stomach acid. Whether oral doses reach injured tissue in people has not been measured; there is no human absorption study.

How long is BPC-157's half-life?

Unmeasured in people. The infusion pilot found plasma levels back to baseline within 24 hours, which bounds it. The four-hour figure that circulates has no published source.

How long does BPC-157 take to work?

No human study has measured onset. Community reports describe pain changes within one to two weeks and courses of four to six weeks, a period over which most soft-tissue injuries improve on their own.

BPC-157 vs TB-500: which is better?

They act by different proposed mechanisms and neither has controlled human evidence for healing. TB-500's parent molecule, thymosin β4, has been in human trials; BPC-157 has not. The comparison page lines up what each record states.

Does BPC-157 cause cancer?

Unknown in either direction. It promotes new blood-vessel growth and growth-factor signalling in animals, which is why the concern exists; no study has tested it in the presence of a tumour.

Does BPC-157 affect blood pressure?

In rats it counteracts both induced hypertension and hypotension through the nitric oxide system. In the two-person human pilot, cardiovascular markers were unchanged over 24 hours. Interactions with blood-pressure drugs are unstudied.

How should BPC-157 be stored?

As a powder, refrigerated or frozen away from light; once dissolved in bacteriostatic water, commonly refrigerated and used within about four weeks. Discard cloudy or discoloured solution.

How many human studies of BPC-157 exist?

Three, all from one clinic in Orlando, all uncontrolled: a 2021 knee injection series, a 2024 series of 12 women with interstitial cystitis, and a 2025 infusion safety pilot in two adults. About 26 people in total.

Why is almost all BPC-157 research from one laboratory?

The compound was developed and has been studied for three decades principally by a group in Zagreb, which accounts for most of the 228 publications. Independent replication is limited, and recent reviews name that concentration as a limitation of the evidence base.

Sources

Full citations. Every claim above links to one of these by its id.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
    Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
    pmid-40131143 · · peer-reviewed
  10. 10
  11. 11
  12. 12
Show the remaining 24 sources
  1. 13
  2. 14
  3. 15
  4. 16
  5. 17
  6. 18
  7. 19
  8. 20
  9. 21
  10. 22
  11. 23
  12. 24
    Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma.
    pmid-35052769 · · peer-reviewed
  13. 25
  14. 26
  15. 27
  16. 28
  17. 29
  18. 30
  19. 31
    Stable gastric pentadecapeptide BPC 157-NO-system relation.
    pmid-23755725 · · peer-reviewed
  20. 32
  21. 33
  22. 34
  23. 35
  24. 36

Reference card

Reference card · generated /compounds/bpc-157
Compound
BPC-157, repair and anti inflammatory
Evidence tier
Observational, human
Indexed publications
228 · 0 RCTs · 0 other clinical trials
Approval
not approved · max phase 1
Routes reported
intragastric, intraperitoneal, intravenous, oral, subcutaneous, topical
Reviewed
Adam Mirando, PharmD,

Study figures are as published in each source and are not recommendations. Print or save this card with its date.

Last reviewed and what changed

Newest first. These are the record's own revision dates, and the same dates feed the sitemap.

  1. · Reviewed by Adam Mirando, PharmD, on 2026-09-25.
  2. · Misattribution check: evidence_table (pmid-42578445): a review's collective sentence about six peptides is not one compound's evidence row. The sources stay in the ledger; only the claims that put another agent's result under this compound were removed.
  3. · Written guide added (9 editorial sections), FAQ expanded to 16, mechanism and reported-use sections, USADA added to the ledger with two verbatim regulatory claims (WADA S0; not approved, no efficacy trials), FDA Category 2 statement pending its document, intent-driven H1 and title. Second page through the content loop.
  4. · Claims drafted extractively from 35 ledger sources by scripts/draft_claims.py: 35 claims, 25 evidence-table rows. Status researched -> draft.
  5. · Claims drafted extractively from 35 ledger sources by scripts/draft_claims.py: 35 claims, 25 evidence-table rows. Status researched -> draft.
  6. · Claims drafted extractively from 35 ledger sources by scripts/draft_claims.py: 37 claims, 25 evidence-table rows. Status researched -> draft.
  7. · Claims drafted extractively from 35 ledger sources by scripts/draft_claims.py: 36 claims, 25 evidence-table rows. Status researched -> draft.
  8. · Evidence fetched from Europe PMC and ChEMBL by scripts/fetch_evidence.py; claims not yet written.